Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

Image of Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

THERAPEUTIC CLASS

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

Williams B, et al - Personal Name;

Optimal drug treatment for patients with resistant hypertension is undefi ned. We aimed to test the
hypotheses that resistant hypertension is most often caused by excessive sodium retention, and that spironolactone
would therefore be superior to non-diuretic add-on drugs at lowering blood pressure.

Availability

Titan Center Location name is not set

REQJ312-01

Available

Detail Information

Series Title: -
Call Number: -
Publisher: : .,
Collation: -
Language: English
ISBN/ISSN: -
Classification: NONE
Content Type: LITERATURE
Media Type: -
Carrier Type: -
Edition: -
Subject(s): Cardiovascular & Hematopoeiteic System
Spironolakton
B Beta
Specific Detail Info: -
Statement of Responsibility: -

Other version/related

No other version available

File Attachment

Read Here

Comments

You must be logged in to post a comment